Orthopediatrics (NASDAQ:KIDS) Rating Increased to Hold at BidaskClub

Orthopediatrics (NASDAQ:KIDS) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, BidAskClub reports.

Several other equities research analysts also recently issued reports on the company. BTIG Research cut their price objective on Verastem to $8.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Zacks Investment Research downgraded Hess Midstream Partners from a “hold” rating to a “sell” rating in a report on Tuesday, May 14th. Finally, Needham & Company LLC set a $69.00 price objective on Genomic Health and gave the company a “buy” rating in a report on Wednesday, June 19th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $46.75.

NASDAQ:KIDS opened at $35.76 on Wednesday. Orthopediatrics has a 52 week low of $25.11 and a 52 week high of $47.82. The company has a current ratio of 8.60, a quick ratio of 6.01 and a debt-to-equity ratio of 0.26. The company has a fifty day simple moving average of $39.03.



Orthopediatrics (NASDAQ:KIDS) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.04). The firm had revenue of $14.66 million during the quarter, compared to analysts’ expectations of $14.67 million. Orthopediatrics had a negative net margin of 16.71% and a negative return on equity of 16.43%. On average, research analysts predict that Orthopediatrics will post -0.45 EPS for the current fiscal year.

Several hedge funds have recently bought and sold shares of KIDS. BNP Paribas Arbitrage SA raised its holdings in shares of Orthopediatrics by 83,150.0% in the 1st quarter. BNP Paribas Arbitrage SA now owns 1,665 shares of the company’s stock valued at $74,000 after buying an additional 1,663 shares during the period. Metropolitan Life Insurance Co. NY purchased a new stake in Orthopediatrics during the 4th quarter worth about $93,000. MetLife Investment Advisors LLC purchased a new stake in Orthopediatrics during the 4th quarter worth about $128,000. Perkins Capital Management Inc. purchased a new stake in Orthopediatrics during the 1st quarter worth about $221,000. Finally, Sigma Planning Corp purchased a new stake in Orthopediatrics during the 1st quarter worth about $280,000. Hedge funds and other institutional investors own 48.63% of the company’s stock.

Orthopediatrics Company Profile

OrthoPediatrics Corp., a medical device company, designs, develops, and markets anatomically appropriate implants and devices for the treatment of children with orthopedic conditions in the United States and internationally. The company's products comprise PediLoc, PediPlates, cannulated screws, PediFlex nail, PediNail products, PediLoc tibia products, anterior cruciate ligament reconstruction systems, locking cannulated blades, locking proximal femurs, RESPONSE Spine systems, Bandloc, and Pediguard.

Recommended Story: Technical Analysis of Stocks and What It Means

Receive News & Ratings for Orthopediatrics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthopediatrics and related companies with MarketBeat.com's FREE daily email newsletter.